Syntheses, Calcium Channel Modulation Effects, and Nitric Oxide Release Studies of O2-Alkyl-1-(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate 4-Aryl(heteroaryl)-1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylates

Drug Development Research

Volumn 60, Issue 3, 2003, Pages 204-216

  Velazquez, Carlos ^a   Vo, Dean ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

1,4 dihydropyridines; Calcium channels; Diazeniumdiolates; Nitric oxide release; Positive inotropes; Smooth muscle relaxation

Indexed keywords

1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITROPYRIDINE 5 CARBOXYLATE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 O BUTYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O BUTYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 TRIFLUOROMETHYLPHENYL)PYRIDINE 5 CARBOXYLATE; 2 O BUTYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (3 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O BUTYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (4 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O BUTYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (BENZOFURAZAN 4 YL)PYRIDINE 5 CARBOXYLATE; 2 O ETHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O ETHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 TRIFLUOROMMETHYLPHENYL)PYRIDINE 5 CARBOXYLATE; 2 O ETHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (3 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O ETHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (4 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O ETHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (BENZOFURAZAN 4 YL)PYRIDINE 5 CARBOXYLATE; 2 O METHY 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (4 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O METHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O METHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 TRIFLUOROMETHYLPHENYL)PYRIDINE 5 CARBOXYLATE; 2 O METHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (3 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O METHYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (BENZOFURAZAN 4 YL)PYRIDINE 5 CARBOXYLATE; 2 O PROPYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O PROPYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (2 TRIFLUOROMETHYLPHENYL)PYRIDINE 5 CARBOXYLATE; 2 O PROPYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (3 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O PROPYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (4 PYRIDYL)PYRIDINE 5 CARBOXYLATE; 2 O PROPYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE 1,4 DIHYDRO 2,6 DIMETHYL 3 NITRO 4 (BENZOFURAZAN 4 YL)PYRIDINE 5 CARBOXYLATE; 4 (2,1,3 BENZOOXADIAZOL 4 YL) 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; CALCIUM CHANNEL; CALCIUM CHANNEL STIMULATING AGENT; CYSTEINE; ESTERASE; NIFEDIPINE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART FUNCTION; IC 50; IN VITRO STUDY; INOTROPISM; NONHUMAN; RAT; SMOOTH MUSCLE; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; SWINE;

EID: 0242331235     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10285     Document Type: Article

References (17)

1. Civelli M, Caruso P, Giossi M, Bergamaschi M, Razzetti R, Bongrani S, Gasco A. 1996. The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363. Br J Pharmacol 118:923-928.
2. Franckowiak G, Bechem M, Schramm M, Thomas G. 1985. The optical isomers of the 1,4-dihydropyridine Bay K 8644 show opposite effect on Ca channels. Eur J Pharmacol 114:223-226.
3. Hrabie JA, Keefer LK. 2002. Chemistry of the nitric oxide-releasing diazeniumdiolate ("nitrosohydroxylamine") functional group and its oxygen-substituted derivatives. Chem Rev 102:1130-1154.
4. Iqbal N, Knaus EE. 1996. Synthesis and smooth muscle calcium channel antagonist effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrooxy or nitrophenyl moiety in the 3-alkyl substituent. Arch Pharm Pharm Med Chem 329:23-26.
5. Medana C, Di Stilo A, Visentin S, Fruttero R, Gasco A, Ghigo D, Bosia A. 1999. NO donor and biological properties of different benzofuroxans. Pharm Res 16:956-960.
6. Ogawa T, Nakazato A, Tsuchida K, Hatayama K. 1993. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing a nitrooxy moiety, at the 3-ester substituent. Chem Pharm Bull 41:108-116.
7. Perez-Reyes E, Schneider T. 1994. Calcium channels: structure, function and classification. Drug Dev Res 33:295-318.
8. Rampe D, Kano JM. 1994. Activators of voltage-dependent L-type calcium channels. Drug Dev Res 33:343-363.
9. Saavedra JE, Billiar TB, Williams DL, Kim Y-M, Watkins SC, Keefer LK. 1997. Targeting nitric oxide (NO) delivery in vivo. Design of a liver selective NO donor prodrug that blocks tumor necrosis factor-α-induced apoptosis and toxicity in the liver. J Med Chem 40:1947-1954.
10. Saavedra JE, Shami PJ, Wang LY, Davies KM, Booth MN, Citro ML, Keefer LK. 2000. Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity. J Med Chem 43:261-269.
11. 2- channels. Nature 303:535-537.
12. Shan R, Howlett SE, Knaus EE. 2002. Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage clamp studies of 2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl) pyridine-5-carboxylate enantiomers. J Med Chem 45:955-961.
13. Tang X, Xian M, Trikha M, Honn KV, Wang PG. 2001. Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents. Tetrahedron Lett 42:2625-2629.
14. Vo D, Matowe WC, Ramesh M, Iqbal N, Wolowyk MW, Howlett SE, Knaus EE. 1995. Synthesis, calcium channel agonist-antagonist modulation activities, and voltage clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers. J Med Chem 88:2851-2859.
15. Vo D, Nguyen JT, McEwen C-A, Shan B, Knaus EE. 2002. Syntheses, calcium channel agonist-antagonist modulation effects and nitric oxide release studies of [3-(benzenesulfonyl)furoxan-4-yloxy]alkyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-trifluoromethylphenyl, benzofurazan-4-yl, 2-, 3-, or 4-pyridyl)-3-pyridinecarboxylates. Drug Dev Res 56:1-16.
16. Wang PG, Xiaoping MX, Wu X, Wu Z, Cai T, Janczuk AJ. 2002. Nitric oxide donors: chemical activities and biological applications. Chem Rev 102:1091-1134.
17. Wei XY, Luckowski EM, Rutledge A, Su CM, Triggle DJ. 1986. Pharmacologic and radioligand binding analysis of the action of 1,4-dihydropyridine activator-antagonist pairs in smooth muscle. J Pharmacol Exp Ther 239:144-153.